Guangzhou Wondfo Biotech Co Ltd (stock code: 300482) was set up in 1992 with an overall registered capital of 342.87 million yuan ($49.28 million), and the company was listed on the innovation board of the Shenzhen Stock Exchange in June 2015, with its market value exceeding over 15 billion yuan.
The company, located at Guangzhou Science City in Huangpu district, covers a total area of 30 mu (2 hectares).
It is devoted to the research and development, manufacturing, and marketing of products for point-of-care testing used in in vitro diagnosis, offering fast diagnosis for customers, as well as products and services in the management of chronic diseases.
It has developed more than 100 products covering areas like infectious diseases, pregnancy, cardiovascular diseases, drugs, tumor diseases, and metabolic diseases, being widely applied in places including hospitals at all levels, pharmacies, and centers for disease control.
The company has established an industrial base for fast diagnosis products that spans 33,000 square meters, with a 5,000 sq m clean production workshop, as well as a global leading production line for fast diagnosis reagents, which have a daily production capacity of 1.5 million.
A branch company and an R&D center have been set up in the United States, while marketing centers have also been established in Germany, Kenya, and Indonesia.
The company has established stable cooperation relationships with brands like Boots and Watsons to jointly offer services for customers from more than 110 countries and regions around the world.
Address: Lizhishan, Guangzhou Science City, Guangzhou, Guangdong province
Official website: http://en.wondfo.com.cn (English)